Moxifloxacin is used as a probe to confirm assay sensitivity in thorough electrocardiogram (ECG) studies. A meal shortens the QT interval and in some instances it is desirable to use moxifloxacin after a meal which may affect PK or PD or both; however there is no published data.Based on a recent peer-reviewed paper published in January 2014 in the British Journal of Clinical Pharmacology Richmond Pharmacology will present its latest findings as an encore poster presentation at the 115th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics (ASCPT), taking place 18th to 22nd March, in Atlanta, Georgia.Join Richmond Pharmacology s Dr Jorg Taubel on 21st March between 11h45 and 13h15 (poster number EII-001) for insight into this new area of research.Read Full PaperView Meeting Program

Latest news

Clinical trials: how taking the pills can pay those bills.

April 20, 2022
The Guardian references Richmond Pharmacology in feature on reimbursement for clinical trial volunteers
Read more

Clinical trials and the patient perspective

May 6, 2022
Successful recruitment and retention of patients - an essential element to delivering clinical studies on time.
Read more

Events

The Future of Healthcare - March 2022

13:30 – 16:00, 22nd March 2022
Discover the intricacies of assessing abnormal liver functions in clinical trial volunteers and gain insights from the latest drug development trials using RNAi therapeutics.
View event